456 related articles for article (PubMed ID: 17363487)
21. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
22. Development of a cyclin-dependent kinase inhibitor devoid of ABC transporter-dependent drug resistance.
Kaliszczak M; Patel H; Kroll SH; Carroll L; Smith G; Delaney S; Heathcote DA; Bondke A; Fuchter MJ; Coombes RC; Barrett AG; Ali S; Aboagye EO
Br J Cancer; 2013 Oct; 109(9):2356-67. PubMed ID: 24071597
[TBL] [Abstract][Full Text] [Related]
23. SRJ09, a promising anticancer drug lead: Elucidation of mechanisms of antiproliferative and apoptogenic effects and assessment of in vivo antitumor efficacy.
Wong CC; Lim SH; Sagineedu SR; Lajis NH; Stanslas J
Pharmacol Res; 2016 May; 107():66-78. PubMed ID: 26940565
[TBL] [Abstract][Full Text] [Related]
24. Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(KIP1).
Patel V; Lahusen T; Leethanakul C; Igishi T; Kremer M; Quintanilla-Martinez L; Ensley JF; Sausville EA; Gutkind JS; Senderowicz AM
Clin Cancer Res; 2002 Nov; 8(11):3549-60. PubMed ID: 12429646
[TBL] [Abstract][Full Text] [Related]
25. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines.
Squires MS; Feltell RE; Wallis NG; Lewis EJ; Smith DM; Cross DM; Lyons JF; Thompson NT
Mol Cancer Ther; 2009 Feb; 8(2):324-32. PubMed ID: 19174555
[TBL] [Abstract][Full Text] [Related]
26. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
Ferguson D; Rodriguez LE; Palma JP; Refici M; Jarvis K; O'Connor J; Sullivan GM; Frost D; Marsh K; Bauch J; Zhang H; Lin NH; Rosenberg S; Sham HL; Joseph IB
Clin Cancer Res; 2005 Apr; 11(8):3045-54. PubMed ID: 15837760
[TBL] [Abstract][Full Text] [Related]
27. Anticancer potential of Hericium erinaceus extracts against human gastrointestinal cancers.
Li G; Yu K; Li F; Xu K; Li J; He S; Cao S; Tan G
J Ethnopharmacol; 2014 Apr; 153(2):521-30. PubMed ID: 24631140
[TBL] [Abstract][Full Text] [Related]
28. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.
Rusnak DW; Lackey K; Affleck K; Wood ER; Alligood KJ; Rhodes N; Keith BR; Murray DM; Knight WB; Mullin RJ; Gilmer TM
Mol Cancer Ther; 2001 Dec; 1(2):85-94. PubMed ID: 12467226
[TBL] [Abstract][Full Text] [Related]
29. HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition.
Selvendiran K; Ahmed S; Dayton A; Kuppusamy ML; Rivera BK; Kálai T; Hideg K; Kuppusamy P
Cancer Biol Ther; 2011 Nov; 12(9):837-45. PubMed ID: 21885917
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of cyclin-dependent kinases by AT7519 enhances nasopharyngeal carcinoma cell response to chemotherapy.
Wei X; Nian J; Zheng J; He Y; Zeng M
Cancer Chemother Pharmacol; 2020 May; 85(5):949-957. PubMed ID: 32279103
[TBL] [Abstract][Full Text] [Related]
31. A novel synthetic compound exerts effective anti-tumour activity in vivo via the inhibition of tubulin polymerisation in A549 cells.
Yan J; Pang Y; Sheng J; Wang Y; Chen J; Hu J; Huang L; Li X
Biochem Pharmacol; 2015 Sep; 97(1):51-61. PubMed ID: 26212540
[TBL] [Abstract][Full Text] [Related]
32. GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models.
Hardwicke MA; Oleykowski CA; Plant R; Wang J; Liao Q; Moss K; Newlander K; Adams JL; Dhanak D; Yang J; Lai Z; Sutton D; Patrick D
Mol Cancer Ther; 2009 Jul; 8(7):1808-17. PubMed ID: 19567821
[TBL] [Abstract][Full Text] [Related]
33. A mixture of amino acids and other small molecules present in the serum suppresses the growth of murine and human tumors in vivo.
Kulcsár G; Gaál D; Kulcsár PI; Schulcz Á; Czömpöly T
Int J Cancer; 2013 Mar; 132(5):1213-21. PubMed ID: 22858865
[TBL] [Abstract][Full Text] [Related]
34. Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models.
Festuccia C; Gravina GL; D'Alessandro AM; Muzi P; Millimaggi D; Dolo V; Ricevuto E; Vicentini C; Bologna M
Endocr Relat Cancer; 2009 Jun; 16(2):401-13. PubMed ID: 19153211
[TBL] [Abstract][Full Text] [Related]
35. MONCPT exerts anti-cancer activities via inducing G2/M arrest and apoptosis in human bladder cancer.
Zhu Y; Jiang H; Zhang C; He QJ; Yang B; Li LJ; Zhu H
Pharmazie; 2009 Dec; 64(12):823-8. PubMed ID: 20095141
[TBL] [Abstract][Full Text] [Related]
36. d-Borneol enhances cisplatin sensitivity via p21/p27-mediated S-phase arrest and cell apoptosis in non-small cell lung cancer cells and a murine xenograft model.
Li J; Yuan J; Li Y; Wang J; Gong D; Xie Q; Ma R; Wang J; Ren M; Lu D; Xu Z
Cell Mol Biol Lett; 2022 Jul; 27(1):61. PubMed ID: 35883026
[TBL] [Abstract][Full Text] [Related]
37. CHM-1, a novel synthetic quinolone with potent and selective antimitotic antitumor activity against human hepatocellular carcinoma in vitro and in vivo.
Wang SW; Pan SL; Huang YC; Guh JH; Chiang PC; Huang DY; Kuo SC; Lee KH; Teng CM
Mol Cancer Ther; 2008 Feb; 7(2):350-60. PubMed ID: 18281518
[TBL] [Abstract][Full Text] [Related]
38. AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts.
Byth KF; Thomas A; Hughes G; Forder C; McGregor A; Geh C; Oakes S; Green C; Walker M; Newcombe N; Green S; Growcott J; Barker A; Wilkinson RW
Mol Cancer Ther; 2009 Jul; 8(7):1856-66. PubMed ID: 19509270
[TBL] [Abstract][Full Text] [Related]
39. The Inhibition Effect of Triptolide on Human Endometrial Carcinoma Cell Line HEC-1B: a in vitro and in vivo Studies.
Ni J; Wu Q; Sun ZH; Zhong J; Cai Y; Huang XE
Asian Pac J Cancer Prev; 2015; 16(11):4571-6. PubMed ID: 26107205
[TBL] [Abstract][Full Text] [Related]
40. Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells.
Agarwal C; Singh RP; Dhanalakshmi S; Tyagi AK; Tecklenburg M; Sclafani RA; Agarwal R
Oncogene; 2003 Nov; 22(51):8271-82. PubMed ID: 14614451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
